• ProMIS’s PMN310 Antibody Therapy Binds Only to Toxic Forms of Amyloid Beta, Study Reports
  • Lack of Awareness of Memory Problems Seen as Sign of Alzheimer’s Risk in Study
  • FDA Places CT1812, Potential Disease-Modifying Alzheimer’s Treatment, on Fast Track
  • Ionis Pharmaceuticals Starts Phase 1/2 Clinical Trial of Alzheimer’s Therapy IONIS-MAPTRx
  • Alzheimer’s Nonprofit, Pfizer, Johns Hopkins Partnering on Therapy Development
  • Menopause May Raise Alzheimer’s Risk Though Metabolic Changes in Brain, Study Says
  • Potential Alzheimer’s Treatments Moving Ahead and Breakthroughs Likely, Scientists Say
  • Alzheimer’s Research Marked by Collaboration and Large-scale Projects, Too
  • New Tool Can Predict Alzheimer’s Better Than Genetic Variant APOE E4 Alone, Study Finds
  • Canadian Study Aims to Improve Early Diagnosis and Treatment
  • Texas Researchers Analyze Why Alzheimer’s Strikes Hispanics Earlier in Life
  • Acadia Is Starting Phase 3 Trial of Nuplazid for Dementia-related Psychosis